To start the interview, Davidson provided some background information about the Company, as well as its goals going forward. He explained that over the past year and a half, the Company has achieved some major milestones including positioning themselves with the DE, having received and recently expanded its Schedule 1 manufacturing license registration.

Jolly then asked whether there are numerous biotech companies getting involved with cannabinoid pharmaceuticals. Davidson explained that previously this was an area that was ignored, however, recently more and more companies are becoming involved. Davidson also explained that dosage regulations within the cannabis industry are still under development. However, he stated that the government and FDA are looking at solutions to this issue carefully and strive to only provide licensure to companies that withhold the highest of standards.

Jolly asked about the Company's recent press release regarding the acquisition of Chemistry Holdings, Inc. and what this means for the Company going forward. Davidson shared that the acquisition represents enormous growth potential. ''We're always looking at creating a more expansive IP portfolio'', stated Davidson. Acquisitions like Chemistry Holdings, Inc. allow the Company to add to its available technology, which can greatly enhance its capabilities and value.

Jolly then inquired about the Company's challenges in the past year. Davidson shared that one of the main challenges the Company faced in 2018 was securing the manufacturing license from the DEA. However, this obstacle has now been overcome. Going forward, one of the main challenges the Company will likely continue to face is the navigation of regulatory changes in the cannabis industry. The Company is confident in its ability to do so by following the required FDA and DEA guidelines as the industry becomes more defined.

Davidson then looked ahead to 2019 and shared his excitement for the Company's potential. He explained that the licensing secured with the DEA allows the Company to expand exponentially throughout 2019. ''We are one of the only drug-delivery companies that have a Schedule 1 manufacturing license from the DEA'', stated Davidson. ''We've seen an influx of partnerships coming to the table at the end of 2018 and 2019'', he added.

To close the interview, Davidson shared that the Company has uniquely positioned itself to become a leader in this fast-growing industry. He added that the Company's IP portfolio is extensive and represents significant value. ''I think we're on the ground floor of something really big and I think our investors have a great opportunity.''

CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and Israel. The company's mission is to improve people's lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.

This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its ''Stock Day'' Podcast, which is the number one radio show of its kind in America. The Uptick Network ''Stock Day'' Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.